miR-150 inhibits terminal erythroid proliferation and differentiation

INTRODUCTION

Erythropoiesis is a hematopoietic process that is tightly regulated via cell lineage specification, proliferation, and differentiation [1–4]. During erythropoiesis, cells undergo several phases, including burst-forming units (BFU-E), colony-forming units (CFU-E), pro-erythroblasts, basophilic erythroblasts, polychromatic erythroblasts, orthochromatic erythroblasts, reticulocytes, and mature red blood cells. The last 6 stages represent terminal erythroid differentiation, characterized by serial cellular changes occurring in membrane-cytoskeleton matrix assembly, cell size, cytoplasmic composition of nucleotide acid and hemoglobin, nuclear-cytoplasmic ratio, and even enucleation [3, 5–7]. Multiple levels of gene expression control and comprehensive gene coordination are required to ensure the proper generation of mature and functional red cells through erythropoiesis [8–15]. Any disruption of erythroid regulatory networks will lead to disease, so identifying and characterizing novel modulators will provide crucial new opportunities for managing erythroid disorders and for the ex-vivo generation of red blood cells.

MicroRNAs (miRNAs), a class of small, non-coding linear RNAs, have been demonstrated to play important roles in posttranscriptional gene regulation in both health and disease, such as cell proliferation and differentiation, ontogenesis and tumorigenesis [16–19]. It has been shown that miRNAs also play a crucial role in erythropoiesis. Overexpression of miR-223 blocked the commitment of erythroid progenitors [20], whereas up-regulating miR-210 promoted erythropoiesis [21]. Deficiency or attenuation of miR-144 and miR-451 has been shown to impair late erythroid maturation, which then leads to splenomegaly, erythroid hyperplasia and mild anemia [22–24]. The functions of miRNAs are target dependent. It has been reported that miR-221/222, miR-24, miR-191 and microRNA-146b-5p modulate erythropoiesis through targeting c-kit, Alk4, Riok3 and Mxi1, and PDGFRA, Klfd, respectively [25–28].

Functional miR-150 is 22 nucleotides long, and its gene is located at chromosome 19q13.33. miR-150 was found to be stimulated and drive megakaryocyte-erythrocyte progenitor differentiation toward megakaryocytes at the expense of erythroid cells in the context of thrombopoietin induction [29]. The targeted regulation of the transcription factor c-Myb (MYB) by miR-150 has been studied in lymphoid, myeloid and megakaryocytic lineages [29–33]. However, it remains unknown whether miR-150 suppression is indispensable for terminal erythroid regulation and how it functions. In this study, we focus on terminal erythroid differentiation, using miR-150 gain- and loss-of-function experiments to elucidate the related mechanisms. We confirm that forced miR-150 expression causes inhibition of erythroid cell differentiation and proliferation, and that miR-150 sustained depression favors terminal erythropoiesis. We identify the gene coding red blood cell membrane protein 4.1R as a new specific target of miR-150 in the late stages of terminal erythropoiesis. This is the first report to highlight the relationship between miRNA and red blood cell membrane protein, providing new insight into terminal erythroid maturation.

RESULTS

miR-150 expression decreases during terminal erythropoiesis

To explore a potential regulatory role of miR-150 during erythropoiesis, human CD34⁺ hematopoietic progenitor cells were first purified from umbilical cord blood and then induced into erythroid lineage differentiation according to the procedure described in the methods section. The induced cells were collected on culture days 0, 4, 6, 8, 10, 12, and 14, and then total RNA was extracted to assess the levels of miR-150. Data obtained from qRT-PCR demonstrate that miR-150 levels dramatically decreased since D 0 and remained much low after D 8 throughout the subsequent time points of erythroid terminal differentiation (Figure 1A), indicating that miR-150 may have a negative role during erythroblast differentiation. The human erythroleukemia cell line K562 has the potential to be induced into erythroid cells with presence of 50 μM hemin and is often used as a model of erythroid differentiation in vitro [28, 34–35]. Total RNA was extracted at 0, 24, 36, and 48 hours after hemin induction, and qRT-PCR was carried out to assess the relative expression of miR-150. Similarly, the relative expression of miR-150 declined significantly after the 24 h time point (Figure 1B).

miR-150 inhibits hemin-induced erythroid differentiation in K562 cells

Based on the above observations, we proceeded to establish miR-150 as a negative regulator during erythropoiesis. K562 cells were transfected with miR-150 mimics, and those cells exhibited robust expression of miR-150 compared to cells transfected with the mimic controls throughout the induction process (Figure 2A). β globin (HBB), γ globin (HBG), ε globin (HBE) and CD235a (GPA, also known as GlyA) were used as erythroid-lineage markers to assess erythroid differentiation after hemin induction. Enforced miR-150 expression produced relatively suppressed erythroid-lineage marker expression levels in each paired condition (Figure 2C and 2D). We also performed benzidine staining to detect the fraction of hemoglobin-containing cells, an indicator of differentiated erythrocytes (blue cells). Compared to the control cells, miR-150 overexpression can reduce the occurrence of hemoglobin-containing erythroid cells: 0.53 ± 0.82% vs. 0.33 ± 0.12% (0 h), 9.40 ± 0.63% vs. 6.63 ± 0.61% (24 h), 36.17 ± 2.40% vs. 28.27 ± 2.29% (36 h), and 51.13 ± 4.08% vs. 33.33 ± 1.80% (48 h) (Figure 2E and 2F). Using flow cytometry, erythroid-lineage cells were also enumerated by measuring CD235a, which indicated a similar negative effect of miR-150. Increased expression of miR-150 resulted in fewer CD235a-positive cells during hemin induction relative to each corresponding control sample (Figure 2G and 2H).

In addition to the miR-150 overexpression, miR-150 was inhibited by the transfection of a miR-150 inhibitor and an inhibitor control into K562 cells. In contrast to miR-150 overexpression, miR-150 inhibition resulted in higher expression of HBB, HBG and HBE relative to the inhibitor control group at each time point after hemin induction (Figure 3B and 3C). Benzidine staining again demonstrated that miR-150 inhibition abrogated the negative control of miR-150 in affecting hemin-induced hemoglobin production, as miR-150 inhibitor yielded more benzidine-positive cells compared to each corresponding inhibitor control group (Figure 3D and 3E). Taken together, all of these findings suggest that miR-150 negatively regulates the hemin-induced erythroid differentiation of K562 cells.

miR-150 inhibits the EPO-dependent differentiation of CD34⁺ cells

To further confirm that miR-150 functions in EPO-induced erythroid differentiation in purified CD34⁺ cells from human cord blood, miR-150 mimics, miR-150 inhibitor, and the corresponding controls were transfected into the erythroid precursors twice, on day 6 and day 8. On day 10, transfected cells were collected and evaluated. Compared to the negative controls for the mimics, transfection of miR-150 mimics significantly increased the functional RNA levels of miR-150 (Figure 4A), and it also suppresses HBB and HBG expression (Figure 4B and 4C). Consistently, the miR-150 inhibitor promotes the expression of HBB and HBG (Figure 4D and 4E). Meanwhile, flow cytometry results demonstrate that transfection of miR-150 mimics produced fewer CD235a-positive cells than did treatment with the mimic controls (73 ± 1.8% vs. 90.3 ± 2.5%, P < 0.05), and miR-150 inhibitor correspondingly produced more CD235a-positive cells than the inhibitor control treatment (94.9 ± 0.6% vs. 90.2 ± 1.1%, P < 0.05) (Figure 4F and 4H). All of these results confirm the negative role of miR-150 during terminal erythroid differentiation.

miR-150 suppresses hemin-induced erythroid proliferation in K562 cells

Because erythroid proliferation is another important aspect of erythropoiesis, we used the stable K562 cell line containing the miR-150 overexpression vector or the control vector to address whether miR-150 modulate erythroid proliferation. Using the CCK-8 cell growth assay, we found that cells overexpressing miR-150 exhibited a delayed growth trend compared to the control groups with presence of hemin induction (Figure 5A). The colony formation experiments produced further evidence of forced miR-150 expression slowing down colony formation by more than 2 folds (P < 0.01, Figure 5B). To discover why forced miR-150 caused inhibition of erythroid proliferation, we hypothesized that ectopic miR-150 expression might lead to apoptosis or cell cycle arrest in erythroid cells. Using flow cytometry, we assayed apoptosis with Annexin V and PI double staining, and we found that miR-150 overexpression significantly increased both early (Annexin V⁺/PI⁻, 18.7 ± 2.7% vs. 5.6 ± 1.3%, P < 0.05) and late (Annexin V⁺/PI⁺, 29.5 ± 9.1% vs. 12.3 ± 4.8%, P < 0.05) apoptosis fractions relative to the control (Figure 5C). Cell cycle detection showed that most cells were blocked at the G0/G1 phase (61.23 ± 0.9%) in erythroid-lineage K562 cells overexpressing miR-150 compared to the control cells (41.80 ± 2.81%) (Figure 5D). Western blot analyses indicated that some important master regulators of apoptosis or cell cycle were altered by forced miR-150 (Figure 5E). Protein levels of Bax and p21 were increased due to miR-150 overexpression relative to the control, whereas those of Bcl-2, CDK4, CDK6 and CyclinD1 were decreased. These alterations are consistent with the functions of these genes, as Bcl-2 is known to be an apoptosis inhibitor, but it interacts with Bax to activate apoptosis [36–39]. p21 has been confirmed to trigger cell cycle arrest at G1, and CDK molecules have the opposite effect [40–43].

4.1R is the target gene of miR-150 in terminal erythropoiesis

Unlike the constant inhibition of miR-150 during terminal erythropoiesis, 4.1R (EPB41) protein expression was continued to increase dramatically during terminal erythropoiesis [44–45]. Bioinformatics analysis predicted that the red blood cell membrane protein 4.1R is a direct target of miR-150, and it contains a complete complementary motif with miR-150 at its mRNA 3’ UTR (Figure 6A). To determine whether the predicted target site of 4.1R for miR-150 is a functional target site, we mutated the seed sequence in the 3’ UTR of 4.1R (Figure 6A). A reporter assay using cotransfection with psiCHECK2–4.1R 3’ UTR, psiCHECK2-mut 4.1R 3’ UTR and pSUPER-miR-150 demonstrated that miR-150 can bind to the 3’ UTR of 4.1R mRNA since the cotransfection resulted in a reduction in the activities of firefly luciferase relative to the empty control, which was then abrogated when the 3’ UTR of 4.1R mRNA is mutated (Figure 6B). miR-191 was also used as a negative miRNA control of miR-150 and was shown to have no effect on 4.1 R, as the cotransfection of psiCHECK2–4.1R 3’ UTR and pSUPER-miR-191 did not influence the luciferase activities (Figure 6B). Meanwhile, we used the confirmed miR-150 target MYB [29–30, 46–47] as a positive target control of the reporter assay, and we observed the expected reduction of luciferase activities after cotransduction with psiCHECK2-MYB 3’ UTR and pSUPER-miR-150 (Figure 6B). Western blotting further confirmed the above observation (Figure 6C). The protein levels of 4.1R were attenuated in K562 cells overexpressing miR-150 relative to control cells.

miR-150 overexpression results in changes to gene profiles that are associated with the regulation of cell differentiation and proliferation

Although 4.1R is shown to be a direct target of miR-150, the erythroid 4.1R knockout mice did not show disorders of early-stage erythropoiesis [48], and siRNA-mediated 4.1R depletion did not affect terminal erythropoiesis (data not shown). MYB is a well known target of miR-150 affecting multiple hematopoietic lineages, while we found that endogenous MYB protein was not increased with the decrease of miR-150 through terminal erythropoiesis in EPO-induced CD34⁺ cells (Supplementary Figure S1). We therefore concluded that the other related genes and pathways involved in regulation of erythroid differentiation and proliferation resulted from ectopic miR-150 expression. Using the latest version of the GeneChip^® Human Genome U133 Plus 2.0 Array transcription chip, 1019 genes were found to be suppressed in the miR-150-overexpressing K562 cells relative to the control group, and the expression levels of another 1045 genes were enhanced by miR-150 overexpression. Gene expression profiling was further verified by qRT-PCR assay of 8 representative down-regulated or up-regulated genes (Supplementary Figure S2). These differently expressed genes function differently, including 47 genes for regulators of cell differentiation (P = 0.002) and 67 genes for regulators of cell proliferation (P = 0.003), mainly included in the ErbB-MAPK-P38 or ErbB-PI3K-AKT signaling pathways (Figure 7A), which were confirmed by Western blot (Figure 7B). Overexpression of miR-150 reciprocally increased expression of genes responsible for apoptosis activation and cell cycle arrest and suppressed expression of genes involved in apoptosis inhibition and cell cycle progression (Figure 7A). For example, compared to controls, miR-150 overexpressing cells showed decreased mRNA levels of Bcl-2 and NAIP, which have previously been described as apoptosis inhibitors [37–38, 49], and elevated levels of Foxo3 and PHLDA1, which are thought to be apoptosis triggers [50–53]. Similarly, exogenous expression of miR-150 up-regulated PRDM5 and BTG3, which have been reported to cause cell cycle arrest and apoptosis [54–57], and down-regulated CCND1 and MTBP, which function to activate cell cycle progression [58–61]. These effects of miR-150 on the regulation of erythroid cell apoptosis and cell cycle progression were confirmed, shown in Figure 5.

Differentially expressed genes were further analyzed for the possibility of being miR-150 direct target genes. Top fifty genes were predicted as direct target genes of miR-150, and most of them were showed interesting annotations such as actin-related, cellular compartment, and cytoskeleton organization, including SORBS3, NF2, ATM, ARHGEF10L, and CXCL12 according to functional annotations of DAVID Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov). 4.1R was excluded from these top fifty target genes as miR-150 overexpression did not result in significant decline of 4.1R mRNA, suggesting that miR-150 could suppress translation of 4.1R directly.

DISCUSSION

During erythropoiesis, a spatiotemporally distinct set of miRNAs is thought to play an important role [22, 62–65]. For instance, weak expression of miR-150 and miR-222 coupled with abundant expression of miR-451, miR-144 and miR-146b has been described in human erythrocytes from EPO-induced CD34⁺ cells and adult bone marrow [25, 28–29]. In our study, we first assessed the expression profile of miR-150 during terminal erythroid differentiation in EPO-induced cord blood CD34⁺ cells or hemin-induced K562 cells, and we observed a constant decline in miR-150 expression. Based on the current research, we propose a hypothesis in which miR-150 is a negative regulator of terminal erythroid differentiation.

To test this hypothesis, human K562 erythroleukemia cells, which have been proven to be a very useful tool for erythroid-lineage development research, were induced into erythroid differentiation with 50 μM hemin [28, 34–35, 66–67]. As expected, forced expression of miR-150 suppressed hemin-dependent erythropoiesis in K562 cells; commitment to hemoglobinization and GPA marking were reduced compared to the controls at each time point. Coincidence, in the loss-of-function experiments, K562 cells transfected with miR-150 inhibitor showed increased erythroid differentiation, as the specific inhibitor induced the expression of hemoglobin genes and the appearance of the erythrocyte membrane protein GPA relative to the mock-inhibited cells. We also performed gain- and loss-of-function experiments with miR-150 at the late phase of EPO-induced erythropoiesis in human CD34⁺ cells, and these results validated the above observations. miR-150 mimics dramatically reduced the expression of hemoglobin genes, while miR-150 inhibitor induced hemoglobinization and the presence of CD235a in EPO-induced erythrocytes on day 10. Surprisingly, forced expression of miR-150 was also shown to restrain erythroid proliferation via inducing apoptosis and cell cycle arrest. Both Western blot and genome-wide expression chip assays confirmed that expression of key molecules involved in apoptosis and cell cycle were altered due to the artificially overexpressed miR-150. These findings confirm that constant down-regulation of miR-150 is essential to ensure successful terminal erythropoiesis. In a recent report, Kouhkan et al. found that the administration of anti-miR-150 was useful for driving megakaryocyte-erythrocyte progenitor differentiation into the erythroid lineage in the absence of growth factors and cytokines [68].

Along with the ongoing down-regulation of miR-150, the red cell membrane protein 4.1R (EPB41) was up-regulated during terminal erythropoiesis [44–45]. Both bioinformatics prediction and the luciferase reporter assay indicated that 4.1R is a target gene of miR-150. miR-150 overexpression reduced the protein level of 4.1R. Erythrocyte membrane formation is crucial to erythrocytes and is involved in erythroid proliferation and differentiation because it enables erythrocytes to circulate in capillaries. 4.1R knockout mice showed that loss of 4.1R compromises membrane skeleton assembly in erythroid progenitors [48, 69–70]. The genome-wide miRNA expression profiling assay via GeneChip^® Human Genome U133 Plus 2.0 Array also indicated a set of possible miR-150 target genes in K562 cells, including SORBS3, NF2, ATM, ARHGEF10L, and CXCL12. Interestingly, these genes are involved in actin-related, cellular compartment, and cytoskeleton organization categories based on GO annotation (http://david.abcc.ncifcrf.gov/). Because each miRNA can target multiple mRNAs, we predict that miR-150 might affect the erythroid lineage via modulating different cellular structure protein-coding genes at different stages. The regulatory mechanism for forming the unique erythrocyte membrane skeleton has not been well studied. This report is the first to indicate the interaction between miRNAs and erythrocyte membrane proteins, which in turn will broaden our understanding of the functions of miRNAs during erythropoiesis.

4.1R was found to be a new target of miR-150, but knockdown of 4.1R did not affect terminal erythropoiesis, and the ratio of nucleated erythroblasts in the 4.1R knockout mouse was normal [48]. The known target of miR-150, MYB [29–30, 46–47], has been reported to promote the early erythropoiesis [71–73]. But MYB is not increased during terminal erythropoiesis in EPO-induced human CD34⁺ cells, the evidence of miR-150 targeting MYB in human physiological terminal erythroblast differentiation is not sufficient. A transcriptional profiling assay provided global insight into the alteration of gene crosstalk introduced by forced miR-150 during terminal erythropoiesis in hemin-induced K562 cells. Here, we found that aberrantly expressed miR-150 suppressed the two major signaling pathways involved in erythroblast proliferation and survival, ErbB-MAPK-p38 and ErbB-PI3K-AKT. Activation of the p38 MAPK pathway has been reported to be a prerequisite for inducing erythroid differentiation of K562 cells [74–75]. TfR1 engagement increased cell sensitivity to EPO to induce erythropoiesis via activating PI3K-AKT pathways [76]. PI3K/AKT signaling is also essential for cell proliferation via inactivating several downstream molecules, such as Foxo3, to inhibit cell growth [51]. Our results indicate that miR-150 overexpression clearly suppressed activation of these two pathways during terminal erythropoiesis, thus explaining the negative effect of miR-150 on erythropoiesis.

In conclusion, constant miR-150 suppression is essential for normal terminal erythroid development, but more research is needed to elucidate upstream regulators, the mechanism underlying the effect of miR-150, and especially the correlation between aberrant miR-150 expression and anemic disorders in the clinic, which are rarely studied.

MATERIALS AND METHODS

Purification and culture of human CD34⁺ cells

CD34⁺ cells were purified from human umbilical cord blood (UCB, provided from normal full-term deliveries after informed consent as approved by the Maternal and Child Health Hospital of Hunan Province, Hunan, China) by positive selection using the CD34⁺ magnetic selective beads system (Miltenyi Biotec, Germany) according to the manufacturer’s instructions. The purification of CD34⁺ cells were checked by CD34 antibody (BD) staining and flow cytometry analysis. Cells were first cultured at 10⁵ cells/ml for 6 days in Serum Free Expansion Medium (SFEM, Stem Cell Technologies) supplemented with 10% fetal bovine serum (FBS, Stem Cell Technologies), 10 ng/ml stem cell factor (SCF), 1 ng/ml IL-3, and 1 IU/ml erythropoietin (Stem Cell Technologies) at 37°C in 5% CO₂, and then cultured for 8 more days in the above complete medium with the presence of 30% FBS and the absence of IL-3 and SCF.

Cell culture

K562 cells (ATCC CCL-243) were obtained from the American Type Culture Collection (ATCC, USA). K562 cells were grown in RPMI 1640 media (Gibco, USA) supplemented with 10% FBS (Gibco, USA) at 37°C in 5% CO₂. Hemin (50 μM, Sigma, USA) was used to induce erythroid differentiation of K562 cells. The growth assay was carried out using Cell Counting Kit-8 (CCK-8) kit (Dojindo, Japan). HEK293 cells (ATCC CRL-1573) were grown in DMEM (Gibco, USA) with 10% FBS (Gibco, USA) at 37°C in 5% CO₂.

Oligonucleotides, plasmid construct and cells transduction

The miR-150 mimic, mimic control, inhibitor and inhibitor control were all obtained from Dharmacon. K562 cells were transiently transduced with these oligonucleotides using DharmFECT1 (Dharmacon, USA) at a final concentration of 100 nM. At 12 hours after transfection, cells were induced by hemin and evaluated at 0, 24, 36 or 48 hours after induction. For human CD34⁺ cells, the miR-150 mimic, mimic control, miR-150 inhibitor or inhibitor control was transduced into cells under the same conditions as above on culture day 6 and repeated one more time on day 8, and the cells were then harvested and assessed on day 10. Recombinant overexpression plasmids for miR-150 and miR-191, including pSUPER-miR-150 and pSUPER-miR-191, were obtained from OligoEngine. K562 cells were first transfected with the miR-150 overexpression vector, pSUPER-miR-150, and then selected by puromycin at the concentration of 1 μg/mL until a stable cell line was generated, and it was then sustained in 200 ng/ml puromycin. 3’ UTRs of EPB41 (4.1R), mutated 3’ UTRs of EPB41 and MYB (c-Myb) were first amplified using PCR primers (Table 1) and then cloned into the psiCHECK2 reporter plasmid (Promega, USA).

RNA extraction and quantitative real-time RT-PCR

Total RNA was isolated using TRIzol reagent (Invitrogen, USA). cDNA was synthesized by Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific, USA). The RT reaction for miR-150 was carried out with stem-loop RT primers (RiboBio, China). Quantitative PCR was performed using SYBR Green qPCR Master Mixes (Takara, China). Relative expression was determined using U6 (primers from RiboBio, China) as the internal control for miRNAs and GAPDH as the internal control for mRNAs of other genes (primers listed in Table 1 and Supplementary Table S1).

Benzidine staining

Benzidine dihydrochloride (Sigma, USA) solution was prepared with 0.5 M ethylic acid. Immediately before use, 1 μl 30% hydrogen peroxide was added to 50 μl benzidine solution. Then, 1 μl fresh whole benzidine solution containing hydrogen peroxide was added in 10 μl K562 cells. Benzidine-positive cells were stained blue, whereas benzidine-negative cells were light yellow.

Western blot analyses

Whole-cell lysates of cultured cells were prepared with RIPA buffer (Thermo Fisher, USA) in the presence of protease inhibitor or PhosStop cocktail (Roche, France). Protein concentration was measured using a Pierce^® BCA protein assay kit (Thermo Fisher, USA). Western blot analysis was performed as previously described, and probed using primary antibodies anti 4.1R (kindly offered by Red Cell Physiology Laboratory, New York Blood Center, NY, USA. Hu 2013), c-myb, p21, Bax, Bcl-2, CDK4, CDK6, CyclinD1, PI3K, p38, p-AKT, AKT, GAPDH and HRP conjugated secondary antibodies (Santa Cruz).

Flow cytometry analyses

All the reactions were performed under conditions of antibody saturation. Unstained cells were used as a negative control. Flow cytometry analyses were finished within 1 h after staining. To analyze the cell-surface protein CD235a, 2 × 10⁵ cells were suspended in 100 μl PBS supplemented with 0.5% BSA and then stained with fluorochrome-conjugated antibodies (CD235a-PE, BD Pharmingen, USA) for 30 min on ice. Cells were washed twice with PBS-0.5% BSA before analysis. For cell cycle analysis, 1 × 10⁶ cells were washed in PBS twice, incubated in 10 μl membrane permeating solution for 1 min on ice, then stained with 100 μl PI for 20 min on ice (in the dark) and re-suspended with 300 μl PBS prior to FACS analysis (Beckman Coulter, USA). Apoptosis analysis was carried out using an Annexin V-FITC/PI double staining kit (Miltenyi Biotec, Germany). After twice PBS washing, 1 × 10⁶ cells were first stained with Annexin V-FITC for 10 min, then stained with PI for 20 min, and kept on ice prior to FACS analysis. All data analysis was performed using the FlowJo 7.5.5 suite of flow cytometry analysis tools.

Soft agar colony formation assay

The bottom layer of a 6-well plate was prepared by pouring 3 mL of Basal Medium Eagle (Sigma, USA) containing 0.5% agar (Becton, Dickinson and Company, USA), 10% serum, 100 μg/ml gentamicin and 200 μg/ml glutamine into each well, and then allowed to solidify. K562 cells at 8 × 10³ cells/ml were re-suspended in medium containing 0.3% agar, 10% serum, 100 μg/ml gentamicin and 200 μg/ml glutamine; 1 mL of this solution was poured as a top layer in each well. The cells were incubated for 15 days at 37°C and 5% CO₂ prior to colony counting.

Luciferase reporter assay

293T cells were plated into 24-well plates at 1.5 × 10⁵ cells/well 24 h before transfection. Then, 30 ng/well recombinant reporter plasmid (psi-EPB41 3’ UTR, psi-mutated EPB41 3’ UTR or psi-MYB 3’ UTR) and recombinant pSUPER-miRNA plasmid expressing miR-150 or miR-191 were co-transfected into each well by using the Attractene transfection reagent (QIAGEN, USA) in triplicate. Luciferase assays were performed 24 h after transfection by using the Dual-Luciferase Reporter Assay System (Promega, USA) on a Berthold AutoLumat LB953 rack luminometer.

Transcriptional profiling and data analysis

Total RNA was extracted and purified from K562 cells stably overexpressing miR-150 and control K562 cells using TRIzol and RNeasy Kit (QIAGEN, USA). cDNAs were prepared and analyzed using GeneChip^® Human Genome U133 Plus 2.0 Array, Affymetrix (Santa Clara, USA) as previously described [77] with technical support from Shanghai Biotechnology Corporation. Direct target genes of miR-150 in present study were selected based on more than 2-fold of reduction together with array detect signal more than 5 in both samples. Genes showing fold changes greater than 2 and array-detected signals greater than 7 in at least one sample were selected as differently expressed genes.

Bioinformatics analysis

All target genes of miR-150 were predicted by both TargetScan Human 6.2 (http://www.targetscan.org) and Human MicroRNA Targets Database (http://www.microRNA.org), and selected based on a prediction score greater than 0.5. The DAVID Functional Annotation Tool (DAVID Bioinformatics Resources 6.7) was used to annotate GO terms and KEGG pathways for differently expressed genes found in CHIP (http://david.abcc.ncifcrf.gov), with GeneCard (http://www.genecards.org/) used as a supplementary reference. The heat map of differently expressed genes was drawn using MultiExperiment Viewer 4.6 (The Institute for Genomic Research, US) software.

Statistical analysis

All data are indicated as mean ± SD. All results were analyzed using SPSS 15.0 software. Significant differences between the groups were determined by analysis of variance and Tukey’s range test. Differences among groups were considered statistically significant at p < 0.05.

ACKNOWLEDGMENTS AND FUNDING

This research is financially supported by the grants from the National Natural Science Foundation of China (Nos. 81270576 and 31101686), New Century Excellent Talents in University (NCET-11–0518), Doctoral fund of ministry of education of China (No.20120162110054).

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Gregory CJ, Eaves AC. Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties. Blood. 1978; 51:527–537.

2. Palis J, Segel GB. Developmental biology of erythropoiesis. Blood Rev. 1998; 12:106–114.

3. Liu J, Mohandas N, An X. Membrane assembly during erythropoiesis. Curr Opin Hematol. 2011; 18:133–138.

4. An X, Schulz VP, Mohandas N, Gallagher PG. Human and murine erythropoiesis. Curr Opin Hematol. 2015; 10.1097/MOH.0000000000000134. [Epub ahead of print]. PMID: 25719574.

5. Chang H, Langer PJ, Lodish HF. Asynchronous synthesis of erythrocyte membrane proteins. Proc Natl Acad Sci USA. 1976; 73:3206–3210.

6. Blikstad I, Nelson WJ, Moon RT, Lazarides E. Synthesis and assembly of spectrin during avian erythropoiesis: stoichiometric assembly but unequal synthesis of alpha and beta spectrin. Cell. 1983; 32:1081–1091.

7. Hanspal M, Hanspal JS, Kalraiya R, Liu SC, Sahr KE, Howard D, Palek J. Asynchronous synthesis of membrane skeletal proteins during terminal maturation of murine erythroblasts. Blood. 1992; 80:530–539.

8. Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene. 2002; 21:3368–3376.

9. Kerenyi MA, Orkin SH. Networking erythropoiesis. J Exp Med. 2010; 207:2537–2541.

10. Khandros E, Weiss MJ. Protein quality control during erythropoiesis and hemoglobin synthesis. Hematol Oncol Clin North Am. 2010; 24:1071–1088.

11. Shearstone JR, Pop R, Bock C, Boyle P, Meissner A, Socolovsky M. Global DNA demethylation during mouse erythropoiesis in vivo. Science. 2011; 334:799–802.

12. Hattangadi SM, Wong P, Zhang L, Flygare J, Lodish HF. From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood. 2011; 118:6258–6268.

13. Juan R. Alvarez-Dominguez Wenqian Hu Bingbing Yuan Jiahai Shi Staphany S. Park Austin A. Gromatzky Alexander van Oudenaarden and Harvey F. Lodish. Global discovery of erythroid long noncoding RNAs reveals novel regulators of red cell maturation. Blood. 2014; 123:570–581.

14. Alvarez-Dominguez JR, Hu W, Yuan B, Shi J, Park SS, Gromatzky AA, van Oudenaarden A, Lodish HF. Global discovery of erythroid long noncoding RNAs reveals novel regulators of red cell maturation. Blood. 2014; 123:570–581.

15. Lessard S, Beaudoin M, Benkirane K, Lettre G. Comparison of DNA methylation profiles in human fetal and adult red blood cell progenitors. Genome Med. 2015; 7:1.

16. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350–355.

17. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281–297.

18. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5:522–531.

19. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell. 2009; 136:26–36.

20. Felli N, Pedini F, Romania P, Biffoni M, Morsilli O, Castelli G, Santoro S, Chicarella S, Sorrentino A, Peschle C, Marziali G. MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematologica. 2009; 94:479–486.

21. Bavelloni A, Poli A, Fiume R, Blalock W, Matteucci A, Ramazzotti G, McCubrey JA, Cocco L, Faenza I. PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. Oncotarget. 2014; 5:4222–4231.

22. Dore LC, Amigo JD, Dos Santos CO, Zhang Z, Gai X, Tobias JW, Yu D, Klein AM, Dorman C, Wu W, Hardison RC, Paw BH, Weiss MJ. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A. 2008; 105:3333–3338.

23. Rasmussen KD, Simmini S, Abreu-Goodger C, Bartonicek N, Di Giacomo M, Bilbao-Cortes D, Horos R, Von Lindern M, Enright AJ, O’Carroll D. The miR-144/451 locus is required for erythroid homeostasis. J Exp Med. 2010; 207:1351–1358.

24. Patrick DM, Zhang CC, Tao Y, Yao H, Qi X, Schwartz RJ, Jun-Shen Huang L, Olson EN. Defective erythroid differentiation in miR-451 mutant mice mediated by 14–3-3zeta. Genes Dev. 2010; 24:1614–1619.

25. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S, Valtieri M, Calin GA, Liu CG, Sorrentino A, Croce CM, Peschle C. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A. 2005; 102:18081–18086.

26. Wang Q, Huang Z, Xue H, Jin C, Ju XL, Han JD, Chen YG. MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. Blood. 2008; 111:588–595.

27. Zhang L, Flygare J, Wong P, Lim B, Lodish HF. miR-191 regulates mouse erythroblast enucleation by down-regulating Riok3 and Mxi1. Genes Dev. 2011; 25:119–124.

28. Zhai PF, Wang F, Su R, Lin HS, Jiang CL, Yang GH, Yu J, Zhang JW. The regulatory roles of microRNA-146b-5p and its target platelet-de rived growth factor receptor α (PDGFRA) in erythropoiesis and megakaryocytopoiesis. J Biol Chem. 2014; 289:22600–22613.

29. Lu J, Guo S, Ebert BL, Zhang H, Peng X, Bosco J, Pretz J, Schlanger R, Wang JY, Mak RH, Dombkowski DM, Preffer FI, Scadden DT, Golub TR. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell. 2008; 14:843–853.

30. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender TP, Rajewsky K. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007; 131:146–159.

31. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A. 2007; 104:7080–7085.

32. Bezman NA, Chakraborty T, Bender T, Lanier LL. miR-150 regulates the development of NK and iNKT cells. J Exp Med. 2011; 208:2717–2731.

33. Morris VA, Zhang A, Yang T, Stirewalt DL, Ramamurthy R, Meshinchi S, Oehler VG. MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitors. PLoS One. 2013; 8:e75815.

34. Wang F, Yu J, Yang GH, Wang XS, Zhang JW. Regulation of erythroid differentiation by miR-376a and its targets. Cell Res. 2011; 21:1196–1209.

35. Li Y, Bai H, Zhang Z, Li W, Dong L, Wei X, Ma Y, Zhang J, Yu J, Sun G, Wang F. The up-regulation of miR-199b-5p in erythroid differentiation is associated with GATA-1 and NF-E2. Mol Cells. 2014; 37:213–219.

36. Fletcher JI, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD, Huang DC, Adams JM. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci U S A. 2008; 105:18081–18087.

37. Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Adv Hematol. 2012; 2012:524308.

38. Slape CI, Saw J, Jowett JB, Aplan PD, Strasser A, Jane SM, Curtis DJ. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome. Blood. 2012; 120:2475–2483.

39. Wang C, Youle RJ. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1’s inhibitory effect on Bak. Oncogene. 2012; 31:3177–3189.

40. Hoeferlin LA, Oleinik NV, Krupenko NI, Krupenko SA. Activation of p21-Dependent G1/G2 Arrest in the Absence of DNA Damage as an Antiapoptotic Response to Metabolic Stress. Genes Cancer. 2011; 2:889–899.

41. Padmakumar VC, Aleem E, Berthet C, Hilton MB, Kaldis P. Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53. Mol Cell Biol. 2009; 29:2582–2593.

42. Baker SJ, Reddy EP. CDK4: A Key Player in the Cell Cycle, Development, and Cancer. Genes Cancer. 2012; 3:658–669.

43. Bisteau X, Paternot S, Colleoni B, Ecker K, Coulonval K, De Groote P, Declercq W, Hengst L, Roger PP. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point. PLoS Genet. 2013; 9:e1003546.

44. Chen K, Liu J, Heck S, Chasis JA, An X, Mohandas N. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc Natl Acad Sci USA. 2009; 106:17413–17418.

45. Hu J, Liu J, Xue F, Halverson G, Reid M, Guo A, Chen L, Raza A, Galili N, Jaffray J, Lane J, Chasis JA, Taylor N, Mohandas N, An X. Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. Blood. 2013; 121:3246–3253.

46. Barroga CF, Pham H, Kaushansky K. Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression. Exp Hematol. 2008; 36:1585–1592.

47. Hussein K, Theophile K, Büsche G, Schlegelberger B, Göhring G, Kreipe H, Bock O. Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk Res. 2010; 34:328–334.

48. Liu J, Zhang J, Ginzburg Y, Li H, Xue F, De Franceschi L, Chasis JA, Mohandas N, An X. Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis. Blood. 2013; 121:e43–49.

49. Katagiri N, Shobuike T, Chang B, Kukita A, Miyamoto H. The human apoptosis inhibitor NAIP induces pyroptosis in macrophages infected with Legionella pneumophila. Microbes Infect. 2012; 14:1123–1132.

50. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96:857–868.

51. Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. Cancer Res. 2013; 73:2189–2198.

52. Neef R, Kuske MA, Pröls E, Johnson JP. Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res. 2002; 62:5920–5929.

53. Nagai MA, Fregnani JH, Netto MM, Brentani MM, Soares FA. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat. 2007; 106:49–56.

54. Guéhenneux F, Duret L, Callanan MB, Bouhas R, Hayette S, Berthet C, Samarut C, Rimokh R, Birot AM, Wang Q, Magaud JP, Rouault JP. Cloning of the mouse BTG3 gene and definition of a new gene family (the BTG family) involved in the negative control of the cell cycle. Leukemia. 1997; 11:370–375.

55. Deng Q, Huang S. PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene. 2004; 23:4903–4910.

56. Duan Z, Person RE, Lee HH, Huang S, Donadieu J, Badolato R, Grimes HL, Papayannopoulou T, Horwitz MS. Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-interacting tumor suppressor PRDM5. Mol Cell Biol. 2007; 27:6889–6902.

57. Lin TY, Cheng YC, Yang HC, Lin WC, Wang CC, Lai PL, Shieh SY. Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16 (INK4a) signaling axis. Oncogene. 2012; 31:3287–3297.

58. Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman JV, Kronenberg HM, Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991; 350:512–515.

59. Boyd MT, Vlatkovic N, Haines DS. A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J Biol Chem. 2000; 275:31883–31890.

60. Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell. 2009; 36:469–476.

61. Vlatković N, El-Fert A, Devling T, Ray-Sinha A, Gore DM, Rubbi CP, Dodson A, Jones AS, Helliwell TR, Jones TM, Boyd MT. Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck. Cancer. 2011; 117:2939–2950.

62. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol. 2007; 35:1657–1667.

63. Choong ML, Yang HH, McNiece I. MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp Hematol. 2007; 35:551–564.

64. Chen SY, Wang Y, Telen MJ, Chi JT. The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. PLoS One. 2008; 3:e2360.

65. Azzouzi I, Moest H, Wollscheid B, Schmugge M, Eekels JJ, Speer O. Deep Sequencing and Proteomic Analysis of the MicroRNA-Induced Silencing Complex in Human Red Blood Cells. Exp Hematol. 2015; 43:382–392.

66. Wu J, Zhou LQ, Yu W, Zhao ZG, Xie XM, Wang WT, Xiong J, Li M, Xue Z, Wang X, Zhang P, Mao BB, Hao DL, Lv X, Liu DP. PML4 facilitates erythroid differentiation by enhancing the transcriptional activity of GATA-1. Blood. 2014; 23:261–270.

67. Shiraishi M, Yamamoto Y, Hirooka N, Obuchi Y, Tachibana S, Makishima M, Tanaka Y. A high concentration of triiodothyronine attenuates the stimulatory effect on hemin-induced erythroid differentiation of human erythroleukemia K562 cells. Endocr J. 2015; 62:431–440.

68. Kouhkan F, Hafizi M, Mobarra N, Mossahebi-Mohammadi M, Mohammadi S, Behmanesh M, Soufi Zomorrod M, Alizadeh S, Lahmy R, Daliri M, Soleimani M. miRNAs: a new method for erythroid differentiation of hematopoietic stem cells without the presence of growth factors. Appl Biochem Biotechnol. 2014; 172:2055–2069.

69. Han BG, Nunomura W, Takakuwa Y, Mohandas N, Jap BK. Protein 4.1R core domain structure and insights into regulation of cytoskeletal organization. Nat Struct Biol. 2000; 7:871–875.

70. Salomao M1, Zhang X, Yang Y, Lee S, Hartwig JH, Chasis JA, Mohandas N, An X. Protein 4.1R-dependent multiprotein complex: new insights into the structural organization of the red blood cell membrane. Proc Natl Acad Sci U S A. 2008; 105:8026–8031.

71. Bianchi E, Zini R, Salati S, Tenedini E, Norfo R, Tagliafico E, Manfredini R, Ferrari S. c-myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression. Blood. 2010; 116:e99–110.

72. Gambone JE, Dusaban SS, Loperena R, Nakata Y, Shetzline SE. The c-Myb target gene neuromedin U functions as a novel cofactor during the early stages of erythropoiesis. Blood. 2011; 117:5733–5743.

73. Bianchi E, Bulgarelli J, Ruberti S, Rontauroli S, Sacchi G, Norfo R, Pennucci V, Zini R, Salati S, Prudente Z, Ferrari S, Manfredini R. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF. Cell Death Differ. 2015; 22:1906–1921.

74. Akel S, Bertolette D, Ruscetti FW. Crosstalk between the Smad and the Mitogen-Activated Protein Kinase Pathways is Essential for Erythroid Differentiation of Erythroleukemia Cells Induced by TGF-β, Activin, Hydroxyurea and Butyrate. J Leuk (Los Angel). 2013; 1:109.

75. Lee YL, Chen CW, Liu FH, Huang YW, Huang HM. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation. PLoS One. 2013; 8:e61939.

76. Coulon S, Dussiot M, Grapton D, Maciel TT, Wang PH, Callens C, Tiwari MK, Agarwal S, Fricot A, Vandekerckhove J, Tamouza H, Zermati Y, Ribeil JA, Djedaini K, Oruc Z, Pascal V, Courtois G, Arnulf B, Alyanakian MA, Mayeux P, Leanderson T, Benhamou M, Cogné M, Monteiro RC, Hermine O, Moura IC. Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia. Nat Med. 2011; 17:1456–1465.

77. Harbig J, Sprinkle R, Enkemann SA. A sequence-based identification of the genes detected by probesets on the Affymetrix U133 plus 2.0 array. Nucleic Acids Res. 2005; 33:e31.